Estrogenic activity of Punica granatum L. peel extract

Satpathy, Swaha; Patra, Amarendra; Purohit, A.

doi:10.1016/s2305-0500(13)60109-8

Cited by 18 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vivo , this compound prevents bone loss after tooth extraction in normal [ 81 ] or diabetic rats [ 82 ] with an increase of ALP expression. In ovariectomized (OVX) rats, an extract of Punica granatum peel has been shown to induce a simultaneous, dose-dependent increase in femoral BMD and uterine weight, suggesting a potent oestrogenic activity of the ellagic acid present in the extract [ 83 ]. These effects were equivalent to the effects of Tamoxifen in increasing femoral mineral content and osteoblast number [ 84 ].…”

Section: Discussionmentioning

confidence: 99%

Pomegranate Peel Extract Prevents Bone Loss in a Preclinical Model of Osteoporosis and Stimulates Osteoblastic Differentiation in Vitro

et al. 2015

View full text Add to dashboard Cite

The nutritional benefits of pomegranate have attracted great scientific interest. The pomegranate, including the pomegranate peel, has been used worldwide for many years as a fruit with medicinal activity, mostly antioxidant properties. Among chronic diseases, osteoporosis, which is associated with bone remodelling impairment leading to progressive bone loss, could eventually benefit from antioxidant compounds because of the involvement of oxidative stress in the pathogenesis of osteopenia. In this study, with in vivo and ex vivo experiments, we investigated whether the consumption of pomegranate peel extract (PGPE) could limit the process of osteopenia. We demonstrated that in ovariectomized (OVX) C57BL/6J mice, PGPE consumption was able to significantly prevent the decrease in bone mineral density (−31.9%; p < 0.001 vs. OVX mice) and bone microarchitecture impairment. Moreover, the exposure of RAW264.7 cells to serum harvested from mice that had been given a PGPE-enriched diet elicited reduced osteoclast differentiation and bone resorption, as shown by the inhibition of the major osteoclast markers. In addition, PGPE appeared to substantially stimulate osteoblastic MC3T3-E1 alkaline phosphatase (ALP) activity at day 7, mineralization at day 21 and the transcription level of osteogenic markers. PGPE may be effective in preventing the bone loss associated with ovariectomy in mice, and offers a promising alternative for the nutritional management of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Pomegranate Peel Extract Prevents Bone Loss in a Preclinical Model of Osteoporosis and Stimulates Osteoblastic Differentiation in Vitro

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It rather suggests a possible effect of indirect antioxidants. In addition, P. granatum polyphenols may also exert modulatory effects in cells through selective actions on different components of the intracellular signalling cascades such as hormones and regulatory proteins that are vital for cellular functions such as growth and proliferation [34] , [35] . This may also explain the observed effects of the P. granatum fruit extract and A. galanga rhizome powder combination.…”

Section: Discussionmentioning

confidence: 99%

An Extract of Pomegranate Fruit and Galangal Rhizome Increases the Numbers of Motile Sperm: A Prospective, Randomised, Controlled, Double-Blinded Trial

Fedder

Jakobsen²,

Giversen³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Pomegranate fruit (Punica granatum) and galangal (Alpinia galanga) have separately been shown to stimulate spermatogenesis and to increase sperm counts and motility in rodents. Within traditional medicine, pomegranate fruit has long been used to increase fertility, however studies on the effect on spermatogenesis in humans have never been published. With this study we investigated whether oral intake of tablets containing standardised amounts of extract of pomegranate fruit and powder of greater galangal rhizome (Punalpin) would increase the total number of motile spermatozoa. The study was designed as a prospective, randomized, controlled, double-blinded trial. Enrolment was based on the mean total number of motile spermatozoa of two ejaculates. The participants delivered an ejaculate after 4–8 days of tablet intake and two ejaculates just before they stopped taking the tablets. Seventy adult men with a semen quality not meeting the standards for commercial application at Nordic Cryobank, but without azoospermia, were included in the study. Participants were randomized to take tablets containing extract of pomegranate fruit (standardised with respect to punicalagin A+B, punicalin and ellagic acid) and freeze-dried rhizome of greater galangal (standardised with respect to 1′S-1′-acetoxychavicol acetate) or placebo on a daily basis for three months. Sixty-six participants completed the intervention (active treatment: n = 34; placebo: n = 32). After the intervention the total number of motile spermatozoa was increased in participants treated with plant extracts compared with the placebo group (p = 0.026). After three months of active treatment, the average total number of motile sperm increased by 62% (from 23.4 to 37.8 millions), while for the placebo group, the number of motile sperm increased by 20%. Sperm morphology was not affected by the treatment. Our findings may help subfertile men to gain an improved amount of motile ejaculated sperm by taking tablets containing preparations of pomegranate fruit extract and rhizome of greater galangal.Trial Registration ClinicalTrials.gov NCT01357044

show abstract

“…Weekly vaginal smears were taken using an eye dropper containing saline, placed on slides and observed under a light microscope after staining with hematoxylin-eosin in order to monitor cellular differentiation. Cells were identified as either leukocytes (indicating a diestrus stage), or nucleated or cornified epithelial cells (indicating an estrous stage) [15,94].…”

Section: Evaluation Of Estrogenic Activitymentioning

confidence: 99%

Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis

Satpathy

Patra

Ahirwar

2015

Journal of Complementary and Integrative Medicine

Self Cite

View full text Add to dashboard Cite

Postmenopausal osteoporosis, a silent epidemic, has become a major health hazard, afflicting about 50% of postmenopausal women worldwide and is thought to be a disease with one of the highest incidences in senile people. It is a chronic, progressive condition associated with micro-architectural deterioration of bone tissue that results in low bone mass, decreased bone strength that predisposes to an increased risk of fracture. Women are more likely to develop osteoporosis than men due to reduction in estrogen during menopause which leads to decline in bone formation and increase in bone resorption activity. Estrogen is able to suppress the production of proinflammatory cytokines like interleukin (IL)-1, IL-6, IL-7 and tumor necrosis factor (TNF-α). This is why these cytokines are elevated in postmenopausal women. In this review article we have made an attempt to collate the various methods and parameters most frequently used for screening of antiosteoporotic activity in postmenopausal osteoporosis. Pertaining to ovariectomized animal model, this is the most appropriate model for studying the efficacy of different drugs to prevent bone loss in postmenopausal osteoporosis.

show abstract

Estrogenic activity of Punica granatum L. peel extract

Cited by 18 publications

References 23 publications

Pomegranate Peel Extract Prevents Bone Loss in a Preclinical Model of Osteoporosis and Stimulates Osteoblastic Differentiation in Vitro

Pomegranate Peel Extract Prevents Bone Loss in a Preclinical Model of Osteoporosis and Stimulates Osteoblastic Differentiation in Vitro

An Extract of Pomegranate Fruit and Galangal Rhizome Increases the Numbers of Motile Sperm: A Prospective, Randomised, Controlled, Double-Blinded Trial

Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis

Contact Info

Product

Resources

About